Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.77USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,110
52-wk High
$8.62
52-wk Low
$4.98

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Announces Proposed Public Offering
Monday, 27 Nov 2017 04:10pm EST 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 11:31am EST 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Aratana Therapeutics reports Q3 loss per share of $0.21
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $6.2 million.  Full Article

Aratana Therapeutics announces launch of Entyce
Friday, 13 Oct 2017 04:05pm EDT 

Oct 13 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution).Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs​.  Full Article

Aratana Therapeutics files for mixed shelf offering of up to $100 mln
Friday, 4 Aug 2017 08:52am EDT 

Aug 4 (Reuters) - Aratana Therapeutics Inc :Aratana therapeutics inc files for mixed shelf offering of up to $100 million - sec filing‍​.  Full Article

Aratana Therapeutics reports Q2 loss per share $0.26
Thursday, 3 Aug 2017 04:30pm EDT 

Aug 3 (Reuters) - Aratana Therapeutics Inc -:Aratana Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.26.Q2 revenue $5.2 million.Aratana Therapeutics - ‍as of June 30, co had about $80.7 million in cash, cash equivalents, restricted cash and short-term investments​.Aratana Therapeutics Inc - ‍for full year 2017, company continues to estimate operating expenses of approximately $45 million​.Aratana-‍believes existing cash,cash equivalents,short-term investments,restricted cash allow co to fund current operating plan, through at least 2018​.Aratana Therapeutics Inc - ‍company's current operating plan contemplates launch of entyce by fall of 2017​.  Full Article

Aratana Therapeutics announces positive results for at-003
Wednesday, 26 Jul 2017 08:30am EDT 

July 26 (Reuters) - Aratana Therapeutics Inc ::Aratana Therapeutics announces positive results for at-003.Aratana Therapeutics Inc - ‍results from study met protocol-defined efficacy success criteria, which were statistically significant for at-003​.Aratana Therapeutics announced positive results of a pivotal field effectiveness study evaluating at-003 in cats under an fda-concurred protocol.  Full Article

Aratana Therapeutics Q1 loss per share $0.34
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Aratana Therapeutics Inc ::Aratana therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.34.Q1 revenue $3.8 million.Aratana therapeutics inc - for full year 2017, company estimates operating expenses of approximately $45 million.  Full Article

Aratana Therapeutics provides update on Entyce
Tuesday, 25 Apr 2017 04:30pm EDT 

April 25 (Reuters) - Aratana Therapeutics Inc -:Aratana Therapeutics provides update on Entyce®.Aratana-Recently met with U.S. Food and drug administration center for veterinary medicine regarding proposed manufacturing transfer of entyce.Believes that it is in agreement with cvm on how to proceed.Aratana Therapeutics Inc - if submission is approved, aratana believes it would be able to make entyce commercially available by fall of 2017.Aratana therapeutics inc - intends to resubmit required prior approval submission in coming weeks relating to entyce.Says believes it would be able to make entyce commercially available by fall of 2017.  Full Article

Aratana Therapeutics posts Q4 loss per share $0.64
Monday, 13 Mar 2017 04:26pm EDT 

Aratana Therapeutics Inc : Aratana Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.64 . Q4 revenue $292,000 .Aratana Therapeutics Inc - expects cash, cash equivalents and short-term investments will fund operations and debt obligations through March 31, 2018.  Full Article